AstraZeneca PLC (AZN)
NASDAQ: AZN · Real-Time Price · USD
67.96
+1.36 (2.04%)
Jan 21, 2025, 4:00 PM EST - Market closed
AstraZeneca Revenue
AstraZeneca had revenue of $13.57B in the quarter ending September 30, 2024, with 18.04% growth. This brings the company's revenue in the last twelve months to $51.21B, up 13.81% year-over-year. In the year 2023, AstraZeneca had annual revenue of $45.81B with 3.29% growth.
Revenue (ttm)
$51.21B
Revenue Growth
+13.81%
P/S Ratio
n/a
Revenue / Employee
$569,588
Employees
89,900
Market Cap
211.12B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 45.81B | 1.46B | 3.29% |
| Dec 31, 2022 | 44.35B | 6.93B | 18.53% |
| Dec 31, 2021 | 37.42B | 10.80B | 40.58% |
| Dec 31, 2020 | 26.62B | 2.23B | 9.16% |
| Dec 31, 2019 | 24.38B | 2.29B | 10.38% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 400.28B |
| Johnson & Johnson | 87.70B |
| Merck & Co. | 63.17B |
| AbbVie | 55.53B |
| Novartis AG | 49.94B |
| Thermo Fisher Scientific | 42.37B |
| Abbott Laboratories | 41.22B |
| Eli Lilly and Company | 40.86B |
AZN News
- 9 hours ago - 5 Ideal Buys From 14 'Safer' January Dividends On Bloomberg 2025 Watch List Of 50 - Seeking Alpha
- 10 hours ago - FDA Approves AstraZeneca's Datroway For Pretreated Breast Cancer Patients - Benzinga
- 11 hours ago - The Schall Law Firm Invites Investors With Losses To Join A Securities Fraud Case Against AstraZeneca PLC - Accesswire
- 1 day ago - AstraZeneca (AZN) Reels from China Investigation and Investor Suit – Hagens Berman - GlobeNewsWire
- 1 day ago - AstraZeneca PLC Is Being Sued For Securities Law Violations And Affected Shareholders Are Urged To Contact The Schall Law Firm - Accesswire
- 3 days ago - AstraZeneca: Diverse Clinical Pipeline Meeting Future Demand, In Undervalued Sector - Seeking Alpha
- 4 days ago - DATROWAY® Approved in the U.S. for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer - Business Wire
- 4 days ago - US FDA approves AstraZeneca's drug for breast cancer - Reuters